Amla (Indian Gooseberry)

An Ayurvedic fruit with lipid data that is better than most people expect and worse-publicized than it deserves.

How Amla (Indian Gooseberry) actually works

Extremely high in vitamin C and tannins, with lipid effects that appear to run through HMG-CoA reductase modulation and improved LDL receptor activity. It also has antiplatelet activity and improves endothelial function in trials.

Where to get Amla (Indian Gooseberry)

The evidence for Amla (Indian Gooseberry)

Graded by what exists behind each claim.

✅ Clinically validated

• RCTs report reductions in LDL and triglycerides and increases in HDL, with several trials showing effect sizes comparable to low-dose statins. Most are small and conducted in India.
• Trials show reduced CRP and improved endothelial function in dyslipidemia.
• Small trials report improved fasting glucose and HbA1c in type-2 diabetes.

📊 Correlative data

• One of the densest natural vitamin C sources, though the vitamin C content is not the likely mechanism.

🧪 Theoretical / extrapolated benefits

• Tannoid principles (emblicanin A and B) inhibit HMG-CoA reductase in preclinical work — the statin target.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Amla (Indian Gooseberry) actually does

Amla is not a vitamin C supplement wearing a fruit costume, and the arithmetic settles that before any mechanism argument starts. Even on a generous reading of a standardized extract at 5% ascorbate, a 500 mg capsule carries about 25 mg of vitamin C — a fifth of one orange, and a quarter of the RDA. Nothing in the lipid literature can run on that, so whatever amla does, it is not doing it as vitamin C.

What is actually in the capsule. The Phyllanthus emblica fruit is dominated by hydrolysable tannins — the gallo-ellagitannin group that includes emblicanin A and emblicanin B, punigluconin and pedunculagin. These are large, heavily hydroxylated polyphenols that do not cross the intestinal wall intact. They hydrolyze in the gut lumen and under colonic bacterial action to gallic acid and ellagic acid, and it is those small phenolics, plus their methylated, sulfated and glucuronidated conjugates, that appear in plasma Manach 2005. Every systemic claim made for this fruit is therefore a claim about metabolites, not about the tannins on the certificate of analysis.

The enzyme the product is sold on, and the enzyme it can actually reach. The claim in circulation — repeated on this site's own amla card — is inhibition of HMG-CoA reductase, the rate-limiting step of hepatic cholesterol synthesis and the statin target. That is a hepatocyte-interior claim, and it requires the inhibitor to reach the liver at a concentration that occupies the enzyme. A tannin that never leaves the lumen cannot do it, and a low-micromolar gallic acid conjugate is a long way from a statin's nanomolar potency at the same site. The mechanism that fits the pharmacokinetics sits one compartment earlier: NPC1L1, the sterol transporter on the enterocyte brush border that ezetimibe blocks, plus ordinary bile-acid and mixed-micelle binding by a polyphenol sitting in the lumen at millimolar concentration. Both are lumen-side, both are compatible with a molecule that is barely absorbed, and neither has been tested for amla in a human. This page therefore separates the claim from the evidence instead of repeating the claim.

The vascular arm is a different mechanism with better human data. The endothelial trial reads digital volume pulse reflection index — a stiffness-sensitive index that falls when small arteries dilate — alongside malondialdehyde, glutathione and nitric oxide Usharani 2013. That marker set describes reduced oxidative consumption of NO rather than increased eNOS output: superoxide and NO react at close to the diffusion limit to form peroxynitrite, so anything that lowers the superoxide burden raises NO availability without touching the synthase. A phenolic circulating at low micromolar is a far more plausible radical sink than it is a statin.

And the pressure hypothesis has already been tested and failed. Gallotannins inhibit angiotensin-converting enzyme in vitro, which made an add-on blood-pressure effect the obvious next prediction. One hundred and fifty patients with essential hypertension took 500 mg of Phyllanthus emblica extract twice daily on top of their existing therapy for 12 weeks, double-blind against placebo, and it moved neither systolic nor diastolic pressure — nor oxidant status, antioxidant capacity, lipid profile, HbA1c or CRP Shanmugarajan 2021. That is the largest and most rigorous amla trial in the cardiovascular literature and it is negative on every endpoint the enthusiastic version of this product is sold on.

Cell, rodent, human — and where it stops

In cells. The hepatic and antioxidant work is done with gallic acid and ellagic acid on hepatocyte and endothelial lines, typically at 10–100 micromolar for 24–48 hours. Hold that number.

In rodents. Fructose-fed and high-fat rat models of metabolic syndrome, extract by oral gavage for four to eight weeks, reporting lower triglycerides and better insulin measures. Rats take doses that scale to several grams a day in a person, and rats synthesize their own ascorbate — which quietly removes one of the two candidate mechanisms from the model before the experiment starts.

In people, and the literature splits cleanly by trial size. The small positive ones: 80 patients with type 2 diabetes took 250 mg or 500 mg of extract twice daily, or atorvastatin 10 mg, for 12 weeks, and reflection index fell by 2.25–9.13% with oxidative markers improving against placebo Usharani 2013; 15 healthy adults took 500 mg/day for 18 weeks in a double-blind crossover with lower von Willebrand factor, lower 8-hydroxy-2'-deoxyguanosine, higher HDL and lower LDL Kapoor 2020; a dyslipidemia pilot on the branded Amlamax extract reported movement in inflammation markers Antony 2008; and pooling the randomized trials gives improvement in lipid profile, glucose and C-reactive protein Setayesh 2023. Then the large negative one: 150 hypertensive patients, 500 mg twice daily, 12 weeks, no effect on blood pressure, lipids, HbA1c, CRP or redox status Shanmugarajan 2021.

The obstacle nobody does out loud is the concentration arithmetic. Manach's review of 97 human bioavailability studies puts peak plasma concentrations for most polyphenols below 1 micromolar after a dietary dose, reaching a few micromolar only for the best-absorbed classes, and almost entirely as glucuronide, sulfate and methylated conjugates rather than as parent compound Manach 2005. Gallic acid sits at the favorable end of that range. The dish ran at 10–100 micromolar of unconjugated parent. That is one to two orders of magnitude on concentration plus a change of chemical species, and it applies to every cell-based mechanism claim made for this fruit, the HMG-CoA one included.

The second obstacle is that the positive results are small and geographically clustered. Fifteen people. Eighty people. A pilot. One country, often with the extract manufacturer involved. Against 150 people in a trial that found nothing Shanmugarajan 2021. When a literature is shaped like that, the honest reading is not “mixed evidence” — it is that the effect, if real, is smaller than the small trials say, because small trials that find nothing are the ones that do not get written up.

Amla (Indian Gooseberry) — which form, and does it matter

The trials are not of “amla”. They are of named, standardized extracts. Amlamax in the inflammation pilot Antony 2008, a standardized aqueous fruit extract in the diabetes trial Usharani 2013, and this site's own card names Saberry and Capros as the trial materials. Those are different preparations standardized to different marker compounds — some to total or low-molecular-weight hydrolysable tannins, some to a single gallate ester. A bottle reading “Amla 500 mg” has told you the species and withheld the only number that would map it onto a trial.

Dried fruit powder is not extract, and the gap is a multiple rather than a nuance. An extract concentrates tannins several-fold over the fruit, so 500 mg of powder and 500 mg of extract are the same mass of two different products. Where a label does not distinguish them, assume powder, because powder is cheaper.

The dose was split in every trial that worked, and that is probably not cosmetic. Twice daily at 250–500 mg per dose Usharani 2013Shanmugarajan 2021Kapoor 2020, which is also the site's own timing guidance for this page. Gallic acid and its conjugates clear fast; 1,000 mg once and 500 mg twice are the same daily milligrams and two different exposure curves.

Take it with the meal it is supposed to act on — if the mechanism is lumen-side. Labeled extrapolation: if amla works at NPC1L1 or by binding bile micelles, it has to be present while the cholesterol is, so with food matters. If it works inside the hepatocyte, timing is irrelevant. The two hypotheses give opposite practical advice and no trial has chosen between them.

What would have to be true, and how you would know it was not

1. ApoB, down 5–10% at 12 weeks on 500 mg twice daily, and read ApoB rather than LDL-C because it counts atherogenic particles instead of the cholesterol riding inside them. The window is set by lipoprotein turnover: the circulating LDL pool re-equilibrates within about three weeks of a change in production or clearance, so 8–12 weeks is well past the transient and matches the trial durations Setayesh 2023.

2. hs-CRP, down, and only if you start high. The pooled analysis has C-reactive protein among the markers that move Setayesh 2023 and the pilot was built around it Antony 2008. Predict a fall of 0.3–0.8 mg/L in someone starting above 2 mg/L, and nothing measurable in someone already below 1 mg/L. There is no room at the bottom, and a reader with a low baseline should not buy this expecting to watch it fall.

3. The prediction that cuts against the product, and it is already half-tested. Predict that blood pressure does not move. The largest amla trial gave 500 mg twice daily to 150 hypertensive patients for 12 weeks and found no change in systolic or diastolic pressure — and no change in the lipid panel, HbA1c, CRP or redox markers either Shanmugarajan 2021. If you are buying amla for blood pressure, the best-powered evidence says you will be disappointed, and a seven-morning home-cuff average before and after 12 weeks will show you that for the price of the cuff. The uncomfortable corollary: that same trial is a negative lipid trial, so prediction 1 above is the site backing the small studies over the large one, and it says so out loud.

4. If the mechanism is lumen-side, a timing experiment should change the result. Take the same daily dose fasted for eight weeks, then with the two largest meals for eight weeks, ApoB at each end. An absorption-blocking mechanism predicts the with-food arm wins clearly. A hepatic mechanism predicts no difference. That is a within-person experiment costing two extra blood draws, and it discriminates between two mechanisms that no trial has separated.

What will fool you: amla lowers fasting glucose in several of these trials, and someone on metformin plus a sulfonylurea who goes shaky at 11 a.m. will read that as the supplement working. It is the interaction in the safety section.

What nobody has tested yet

The experiment that would settle the whole mechanism argument costs two extra assays on blood already being drawn. Serum lathosterol and desmosterol track cholesterol synthesis; serum campesterol and sitosterol track cholesterol absorption. Give 500 mg of standardized extract twice daily for 30 days with those four sterols measured before and after. If synthesis markers fall, the HMG-CoA story on the card is right and amla is statin-like. If absorption markers fall instead, amla is ezetimibe-like and every sentence written about the statin target is pointing at the wrong organ. This has never been done for any amla preparation.

Nobody has reconciled the 150-patient null with the small positives. The obvious explanation is baseline: the null trial ran in treated hypertensives whose lipids and pressure were already being managed pharmacologically Shanmugarajan 2021, while the positive trials ran in people with room to move Usharani 2013. That is a testable claim — one trial stratified by baseline LDL and by statin use would say whether amla only works where nothing else is working, which is a much narrower product than the one on the shelf.

Lp(a) has never been measured in an amla trial. It rides on the same tube as the lipid panel, it is genetically fixed for most people, and it is the cleanest way to distinguish a real particle effect from a cholesterol-content shuffle. Adding it costs one line on a requisition form.

And nobody has separated the tannin from the ascorbate. Three arms — whole extract, tannin-depleted extract, and matched ascorbate alone — would say in twelve weeks whether the vitamin C story is a marketing residue or a minority contributor. The arithmetic at the top of this page says residue. Nobody has checked.

Amla (Indian Gooseberry) — its own safety story, not its category's

The bleeding risk here is not a category warning — a trial measured it and printed it as a benefit. The 18-week crossover reported improved blood fluidity with reduced von Willebrand factor and thrombin-related markers in healthy adults on 500 mg/day Kapoor 2020. Read that as pharmacology rather than marketing and it says amla has measurable antithrombotic activity at a label dose. That is additive with warfarin, with the direct oral anticoagulants, with clopidogrel and with aspirin at any dose, and it is pharmacodynamic — it does not show up as a changed drug level, it shows up as bruising, nosebleeds or a raised INR. Stop at least two weeks before surgery or dental extraction, and volunteer it, because the pre-op questionnaire asks about prescriptions and not about fruit.

Oxalate, stated precisely enough to act on. Amla is a high-oxalate fruit and calcium-oxalate is the commonest stone. A previous stone is the exclusion. For everyone else the mitigation is boring and effective: take it inside a calcium-containing meal, which binds oxalate in the gut lumen before it can be absorbed, and drink enough that urine stays pale. The ascorbate content at 500 mg of extract is far too small to be an independent oxalate source, which is the part of the oxalate story that usually gets overstated.

Iron, which nobody mentions and the chemistry makes unavoidable. Hydrolysable tannins chelate non-heme iron in the gut lumen — the same reaction that makes tea a documented iron-absorption inhibitor. A twice-daily-with-food schedule puts a gram of gallotannin into the same meal as the iron. If you are menstruating, vegetarian, or carrying a ferritin under 30 ng/mL, put two hours between amla and any iron supplement or iron-heavy meal, and recheck ferritin at six months.

Glucose, additive rather than alternative. Fasting glucose and HbA1c move in several of these trials Setayesh 2023, and the diabetes trial ran in people already on treatment Usharani 2013. On insulin or a sulfonylurea that is additive hypoglycemia risk, and the answer is a glucose meter before and after rather than an assumption that a fruit is too weak to matter.

Loose stools at higher doses are the usual complaint and are a tannin effect rather than an allergy. This is not a statin substitute where a statin is indicated.

Sources read for this page

• Usharani P, et al. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study.. Diabetes, Metabolic Syndrome and Obesity 2013 · PMID 23935377
• Kapoor MP, et al. Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study.. Contemporary Clinical Trials Communications 2020 · PMID 31890983
• Antony B, et al. A Pilot clinical study to evaluate the effect of Emblica officinalis extract (Amlamax) on markers of systemic inflammation and dyslipidemia.. Indian Journal of Clinical Biochemistry 2008 · PMID 23105791
• Setayesh L, et al. The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.. Diabetes & Metabolic Syndrome 2023 · PMID 36934568
• Shanmugarajan D, et al. Antihypertensive and pleiotropic effects of Phyllanthus emblica extract as an add-on therapy in patients with essential hypertension-A randomized double-blind placebo-controlled trial.. Phytotherapy Research 2021 · PMID 33570228
• Manach C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.. American Journal of Clinical Nutrition 2005 · PMID 15640486

How you would know if it worked

Amla (Indian Gooseberry) — safety & side effects

Bloodwork to run alongside Amla (Indian Gooseberry)

Baseline first, then again at 8–12 weeks.

The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.

Check results you already have → · All 103 markers A–Z

Amla (Indian Gooseberry) — frequently asked questions

What Amla (Indian Gooseberry) is used for

Amla (Indian Gooseberry) appears under 1 goal in the goal router.

Related Cardiovascular supplements

← Browse the full Supplement Vault

↑ Back to on this page